Fenofibrate 67 MG Oral Capsule — RxCUI 200311
RxNorm drug concept · Semantic clinical drug
RxCUI 200311
Semantic clinical drug · SCD
● Current RxNorm concept 34 FDA products
69 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI200311
Official nameFenofibrate 67 MG Oral Capsule
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped34
Package NDCs mapped69
Reported Medicaid activity (SDUD)133,327 prescriptions · 43 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Fenofibrate: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Fenofibrate helps bring your blood lipid levels into a healthier range. Depending on your situation, that might mean lowering your triglycerides, bringing down your LDL (bad) chole...
- What exactly is fenofibrate supposed to do for me?
- It depends on which form you have. Lipofen capsules should be taken with food. Antara capsules and most fenofibrate tablets can be taken with or without food. Some film-coated feno...
- Does it matter if I take this with food or on an empty stomach?
🕸️ Concept Web — How Fenofibrate 67 MG Oral Capsule Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Fenofibrate 67 MG Oral Capsule
RxCUI 200311 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Fenofibrate
8703IN
-
Fenofibrate
-
Dose forms 6
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Fenofibrate Oral Capsule
379815SCDF -
Fenofibrate Oral Product
1159042SCDG -
Fenofibrate Pill
1159043SCDG -
Oral Capsule
316965DF -
Oral Product
1151131DFG -
Pill
1151133DFG
-
Fenofibrate Oral Capsule
-
Clinical & branded drugs 1
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Fenofibrate 67 MG
379816SCDC
-
Fenofibrate 67 MG
Showing up to 8 concepts per family — 8 of 8 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Fenofibrate 67 MG
SCDC · 379816 -
Fenofibrate Oral Capsule
SCDF · 379815 -
Fenofibrate Oral Product
SCDG · 1159042 -
Fenofibrate Pill
SCDG · 1159043
📦 FDA Products & Package NDCs
34 products · 69 package NDCs
69 package NDCs map to RxCUI 200311 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 62332-0085-30 | 30 CAPSULE in 1 BOTTLE (62332-085-30) | Fenofibrate | Alembic Pharmaceuticals Inc. | 2020-10-22 |
| 62332-0085-31 | 100 CAPSULE in 1 BOTTLE (62332-085-31) | Fenofibrate | Alembic Pharmaceuticals Inc. | 2020-10-22 |
| 62332-0085-71 | 500 CAPSULE in 1 BOTTLE (62332-085-71) | Fenofibrate | Alembic Pharmaceuticals Inc. | 2020-10-22 |
| 62332-0086-30 | 30 CAPSULE in 1 BOTTLE (62332-086-30) | Fenofibrate | Alembic Pharmaceuticals Inc. | 2020-10-22 |
| 62332-0086-31 | 100 CAPSULE in 1 BOTTLE (62332-086-31) | Fenofibrate | Alembic Pharmaceuticals Inc. | 2020-10-22 |
| 62332-0086-71 | 500 CAPSULE in 1 BOTTLE (62332-086-71) | Fenofibrate | Alembic Pharmaceuticals Inc. | 2020-10-22 |
| 67046-1538-03 | 30 CAPSULE in 1 BLISTER PACK (67046-1538-3) | Fenofibrate | Coupler LLC | 2025-03-25 |
| 68462-0580-01 | 100 CAPSULE in 1 BOTTLE (68462-580-01) | fenofibrate | Glenmark Pharmaceuticals Inc., USA | 2017-04-07 |
| 68462-0581-01 | 100 CAPSULE in 1 BOTTLE (68462-581-01) | fenofibrate | Glenmark Pharmaceuticals Inc., USA | 2017-04-07 |
| 68462-0582-01 | 100 CAPSULE in 1 BOTTLE (68462-582-01) | fenofibrate | Glenmark Pharmaceuticals Inc., USA | 2017-04-07 |
| 69097-0894-02 | 30 CAPSULE in 1 BOTTLE, PLASTIC (69097-894-02) | Fenofibrate | Cipla USA Inc., | 2017-03-30 |
| 69097-0894-07 | 100 CAPSULE in 1 BOTTLE, PLASTIC (69097-894-07) | Fenofibrate | Cipla USA Inc., | 2017-03-30 |
| 69097-0894-15 | 1000 CAPSULE in 1 BOTTLE, PLASTIC (69097-894-15) | Fenofibrate | Cipla USA Inc., | 2017-03-30 |
| 69097-0895-02 | 30 CAPSULE in 1 BOTTLE, PLASTIC (69097-895-02) | Fenofibrate | Cipla USA Inc., | 2017-03-30 |
| 69097-0895-07 | 100 CAPSULE in 1 BOTTLE, PLASTIC (69097-895-07) | Fenofibrate | Cipla USA Inc., | 2017-03-30 |
| 69097-0895-12 | 500 CAPSULE in 1 BOTTLE, PLASTIC (69097-895-12) | Fenofibrate | Cipla USA Inc., | 2017-03-30 |
| 69097-0896-02 | 30 CAPSULE in 1 BOTTLE, PLASTIC (69097-896-02) | Fenofibrate | Cipla USA Inc., | 2017-03-30 |
| 69097-0896-07 | 100 CAPSULE in 1 BOTTLE, PLASTIC (69097-896-07) | Fenofibrate | Cipla USA Inc., | 2017-03-30 |
| 69097-0896-12 | 500 CAPSULE in 1 BOTTLE, PLASTIC (69097-896-12) | Fenofibrate | Cipla USA Inc., | 2017-03-30 |
Observed labelers:
Alembic Pharmaceuticals Inc. (9) ·
Alembic Pharmaceuticals Limited (9) ·
Bostal LLC (9) ·
Cipla USA Inc., (9) ·
Torrent Pharmaceuticals Limited (9) ·
Ajanta Pharma USA Inc. (6)
· +6 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.